EGI
SPRY icon

EAM Global Investors’s ARS Pharmaceuticals SPRY Stock Holding History

EAM Global Investors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-183,452
Closed -$1.56M – 175
2022
Q4 		$1.56M Buy
+183,452
New +$1.19M 0.4% 132

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM Global Investors's SPRY Position: Q1 2023 in Review

EAM Global Investors sold out of ARS Pharmaceuticals (SPRY) in Q1 2023, closing a stake of 183,452 shares — an estimated $1.56M sold.

EAM Global Investors first reported a position in SPRY in Q4 2022 and held it in 1 quarter. The position peaked at $1.56M in Q4 2022. 89 funds tracked by Wall St. Rank hold SPRY as of Q1 2023.

  • EAM Global Investors reported no remaining ARS Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • EAM Global Investors sold 183,452 ARS Pharmaceuticals shares in Q1 2023, an estimated $1.56M.
  • EAM Global Investors first reported a position in ARS Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • EAM Global Investors's ARS Pharmaceuticals position peaked at $1.56M in Q4 2022.
  • 89 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2023.

Based on EAM Global Investors's 13F filing for Q1 2023, filed 15 May 2023.